Literature DB >> 7922369

A three-dimensional model of hepatitis delta virus ribozyme based on biochemical and mutational analyses.

N K Tanner1, S Schaff, G Thill, E Petit-Koskas, A M Crain-Denoyelle, E Westhof.   

Abstract

BACKGROUND: Hepatitis delta virus (HDV), which has a single-stranded RNA genome about 1700 nucleotides long, is a satellite virus of hepatitis B, and is associated with a high incidence of fulminant hepatitis and death in infected humans. Like certain pathogenic subviral RNAs that infect plants, HDV RNA features a closed-circular conformation, a rolling-circle mechanism of replication and RNA-catalyzed self-cleaving reactions of both genomic and anti-genomic strands in vitro. The catalytic domains cannot be folded into either the hammerhead or hairpin secondary-structure motifs that have been found in other self-cleaving RNAs.
RESULTS: A pseudoknot secondary-structure model has been suggested for the catalytic domain (ribozyme) of HDV RNA. We conducted extensive mutational analyses of regions of the HDV ribozyme predicted in this model to be single stranded, and found that several of them are important for catalytic activity. We used these data, sequence comparisons between different isolates and previously published structural analyses to produce a computer graphic model of the three-dimensional architecture of the HDV ribozyme.
CONCLUSIONS: Our model supports the pseudoknotted structure and rationalizes several observations relating to the lengths of the various stems and the sequence requirements of the single-stranded regions. It also provides insight into the catalytic mechanism of the HDV ribozyme. We specifically propose that residues C75, U20 and C21 form the basis of the catalytic region and are close to the cleavable phosphate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7922369     DOI: 10.1016/s0960-9822(00)00109-3

Source DB:  PubMed          Journal:  Curr Biol        ISSN: 0960-9822            Impact factor:   10.834


  51 in total

1.  Modeling RNA folding paths with pseudoknots: application to hepatitis delta virus ribozyme.

Authors:  H Isambert; E D Siggia
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

Review 2.  On the wobble GoU and related pairs.

Authors:  B Masquida; E Westhof
Journal:  RNA       Date:  2000-01       Impact factor: 4.942

3.  Involvement of a cytosine side chain in proton transfer in the rate-determining step of ribozyme self-cleavage.

Authors:  I H Shih ; M D Been
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

4.  Kinetic and binding analysis of the catalytic involvement of ribose moieties of a trans-acting delta ribozyme.

Authors:  Karine Fiola; Jean-Pierre Perreault
Journal:  J Biol Chem       Date:  2002-05-15       Impact factor: 5.157

5.  Analysis of the cleavage reaction of a trans-acting human hepatitis delta virus ribozyme.

Authors:  H Fauzi; J Kawakami; F Nishikawa; S Nishikawa
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

6.  A domain-based model for predicting large and complex pseudoknotted structures.

Authors:  Song Cao; Shi-Jie Chen
Journal:  RNA Biol       Date:  2012-02-01       Impact factor: 4.652

Review 7.  Two distinct catalytic strategies in the hepatitis δ virus ribozyme cleavage reaction.

Authors:  Barbara L Golden
Journal:  Biochemistry       Date:  2011-10-17       Impact factor: 3.162

8.  Chemical rescue, multiple ionizable groups, and general acid-base catalysis in the HDV genomic ribozyme.

Authors:  Anne T Perrotta; Timothy S Wadkins; Michael D Been
Journal:  RNA       Date:  2006-05-11       Impact factor: 4.942

9.  Biphasic folding kinetics of RNA pseudoknots and telomerase RNA activity.

Authors:  Song Cao; Shi-Jie Chen
Journal:  J Mol Biol       Date:  2007-01-09       Impact factor: 5.469

10.  A pseudoknot ribozyme structure is active in vivo and required for hepatitis delta virus RNA replication.

Authors:  K S Jeng; A Daniel; M M Lai
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.